
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics Inc. is advancing its pipeline of innovative therapies, particularly through its ReSonance program, which focuses on auditory neuron transplant candidates for addressing auditory neuropathy and enhancing cochlear implant effectiveness. The company has successfully progressed to the next preclinical stages with the development of targeted auditory neuronal cell types and the generation of novel intellectual property, achieved with minimal incremental investment. Furthermore, a committed funding of up to $12 million from William Demant Invest provides significant financial backing to support these critical advancements in the company's therapeutic pipeline.
Bears say
Lineage Cell Therapeutics Inc is facing significant challenges due to its reliance on clinical-stage products that have not yet generated revenue or achieved commercial viability, which raises concerns about the sustainability of its funding. The company's development pipeline, while innovative, is still in early stages, with OpRegen and other therapies undergoing clinical trials that inherently carry risks of delays or failures, impacting investor confidence. Additionally, the competitive landscape in biotechnology and the need for substantial capital infusion for continued research and development further contribute to a negative outlook on the company's financial viability.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares